How ACE-031 Myostatin Inhibitor Effects Muscle (Explained)

Written by: Billy White

|

|

Time to read 3 min

Evidence-based. Last updated: November 23, 2023

ACE-031 is a myostatin inhibitor

It promotes muscle growth and reduces atrophy signalling

It's being researched for muscle wasting conditions like Cachexia and age-related muscle loss, it may be effective for these

ACE-031, a fusion protein comprising activin receptor type IIB and IgG1-Fc, is at the forefront of research in muscle growth and development.


Its primary mechanism is through the inhibition of myostatin, a protein that naturally limits muscle growth.


This inhibition promotes increased muscle mass, presenting ACE-031 as a potential therapeutic agent, especially in muscle-wasting conditions like Duchenne muscular dystrophy (DMD).


Clinical studies have highlighted its ability to enhance muscle volume significantly, making it a promising candidate for treating various myopathies.


However, comprehensive research and understanding of its long-term safety and side effects are crucial before it can be widely adopted in clinical settings.

What Is ACE-031?

ACE-031 is a novel and intriguing peptide with significant implications for muscle growth and development.


Structurally, it is a fusion protein composed of activin receptor type IIB and IgG1-Fc.

This composition enables ACE-031 to selectively bind to myostatin and related ligands.


Myostatin is a well-known protein that plays a crucial role in regulating muscle growth.


By inhibiting myostatin, ACE-031 opens avenues for increased muscle development, making it a promising candidate for the treatment of muscle-wasting diseases.

Mechanism of Action

The primary mechanism of action of ACE-031 involves its interaction with myostatin and other similar proteins.


Myostatin naturally limits muscle growth, acting as a regulatory protein to prevent excessive muscle development.


However, in conditions where muscle growth is desirable or necessary, such as in muscle wasting diseases, this limitation is counterproductive.


ACE-031 binds to myostatin, thereby inhibiting its activity, having a similar effect to reducing myostatin levels.


This inhibition leads to an increase in muscle growth and strength by allowing the body's muscle-building processes to proceed with less restriction.

Clinical Implications

One of the key areas of interest for ACE-031 is its potential application in treating Duchenne muscular dystrophy (DMD), a severe form of muscle-wasting disease.


In clinical trials, ACE-031 has shown promise in increasing muscle mass in individuals with DMD.


By inhibiting myostatin, ACE-031 can potentially counteract the muscle degeneration seen in this disease, leading to improved muscle strength and function.


This is particularly significant as there are few effective treatments currently available for DMD and other similar myopathies.

Effects on Muscle Mass

The most notable effect of ACE-031 is its ability to increase muscle mass.


Clinical studies have demonstrated that administration of ACE-031 can lead to significant gains in muscle volume.


This is particularly beneficial for individuals suffering from diseases characterized by muscle wasting or weakness.


Beyond therapeutic applications, the potential of ACE-031 in enhancing muscle mass also raises interest in contexts such as sports and bodybuilding, although its use in these areas raises ethical and regulatory concerns.

Safety and Side Effects

As with any therapeutic agent, the safety profile of ACE-031 is an important consideration.


Clinical trials have provided valuable insights into the tolerability and side effects associated with its use.


While the results have been promising, it is crucial to conduct further research to fully understand the long-term implications and potential adverse effects of ACE-031.

Written by: Billy White

Billy White is an experienced personal trainer, an aspiring bodybuilder, and loves to research. He's passionate about serving the fitness and health community with the highest-quality, study-backed information.

Disclaimer

The content available on gymyeti.com is intended for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health providers with any questions you may have regarding a medical condition or health concerns. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

The information on gymyeti.com has not been evaluated by the Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease or health condition. gymyeti.com does not guarantee the accuracy, completeness, or usefulness of any content or endorse any specific tests, products, procedures, opinions, or other information that may be mentioned on the site.

 

See the full disclaimer on our terms of service page here.

References

  1. Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017 Apr;55(4):458-464. doi: 10.1002/mus.25268. Epub 2016 Dec 23. PMID: 27462804.
  2. Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013 Mar;47(3):416-23. doi: 10.1002/mus.23539. Epub 2012 Nov 21. PMID: 23169607.
  3. Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar R, Underwood KW, Pearsall RS, Lachey JL. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol (1985). 2010 Sep;109(3):635-42. doi: 10.1152/japplphysiol.00866.2009. Epub 2010 May 13. PMID: 20466801; PMCID: PMC2944638.